<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55153">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01673932</url>
  </required_header>
  <id_info>
    <org_study_id>UCB-IS-01</org_study_id>
    <nct_id>NCT01673932</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke</brief_title>
  <official_title>Phase 1 Clinical Trial to Establish the Safety and Feasibility of Transplants of Umbilical Cord Blood Mononuclear Cells in Chronic Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Spinal Cord Injury Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prince of Wales Hospital, Shatin, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Mary Hospital, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>StemCyte, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China Spinal Cord Injury Network</source>
  <oversight_info>
    <authority>Hong Kong: Ethics Committee</authority>
    <authority>Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to assess the safety and possible efficacy of umbilical cord blood mononuclear
      cells (UCBMC) treatment of chronic ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label randomized controlled study.  Subjects fulfill the inclusion and
      exclusion criteria will be recruited and randomly assigned to treatment group or control
      group.  The subjects in the treatment group will receive transplant of UCBMC isolated from
      HLA-matched cord blood unit.  The subjects in the control group will receive standard
      routine treatment which do not involve interventional treatment.  All subjects will be
      followed up for at least 12 months.  Long-term follow-up will be carried up to 36 months if
      applicable.

      The adverse events and safety parameters will be record and assessed.  In addition, the
      stroke scores , gait and brain MRI will be obtained before and after the treatment to assess
      the safety and potential treatment effect of UCBMC in chronic ischemic stroke.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale</measure>
    <time_frame>12 months, up to 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change from the baseline in National Institutes of Health Stroke Scales</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Outcome</measure>
    <time_frame>12 months, up to 36 months followup</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint will be the safety of UCBMC treatment as determined by the incidence and severity of adverse events, clinically-significant changes on clinical laboratory tests, vital signs, physical and neurological examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>European Stroke Scale (ESS)</measure>
    <time_frame>12 months, up to 36 months if applicable</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change from baseline in ESS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Min-Mental State Examination (MMSE)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change from baseline in MMSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change in MRI between pre-treatment and post-treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Stroke</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Brain Ischemia</condition>
  <arm_group>
    <arm_group_label>UCBMC, surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will receive standard treatment which does not involve interventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCBMC</intervention_name>
    <description>Inject 10-40 million viable UCBMC (umbilical cord blood mononuclear cells) suspension into brain adjacent to the infract</description>
    <arm_group_label>UCBMC, surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <arm_group_label>UCBMC, surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  either gender, age 35 -65 years old;

          -  ischemic stroke &gt; 6 months and &lt; 60 months;

          -  stable hemiplegia or hemiparesis condition &gt; 3 months;

          -  stroke-induced clinical deficits affecting motor, perceptual, or language functions,
             with NIHSS of 5-15;

          -  stroke in the middle cerebral artery territory;

          -  subjects able to understand, sign and date the informed consent form

        Exclusion Criteria:

          -  non-ischemic mechanism, subarachnoid hemorrhage, primary intracerebral or
             intraventricular hemorrhage;

          -  pregnant or lactating women;

          -  alcohol or drug abuse in previous 3 months;

          -  significant medical diseases or infections;

          -  current participation in another investigational study or taking any investigational
             drug within last 4 weeks before the screening;

          -  unavailability of HLA-matched umbilical cord blood unit;

          -  investigator suggests that the subject would not suitable to perform the surgery or
             participate in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waisang Poon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Chinese University of Hong Kong, Prince of Wales Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilberto Ka Kit Leung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong, Queen Mary Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karrie Kiang</last_name>
      <phone>+852 2255 4468</phone>
      <email>mykiang@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Gilberto Ka Kit Leung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waisang Poon, MD</last_name>
      <phone>+852 2632 1625</phone>
      <email>stroke-study@surgery.cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Waisang Poon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>August 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>chronic stroke</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>umbilical cord blood</keyword>
  <keyword>umbilical cord blood mononuclear cells</keyword>
  <keyword>transplant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
